Novogene

Novogene specializes in the application of advanced molecular biotechnology and high-performance computing in the research fields of life science and human health. Established in March 2011, Novogene strives to become a global leader in providing genetic science services and technology products. Novogene has set up operations and laboratories in the United States, the United Kingdom, Netherlands, Germany, as well as in China, Singapore and Japan. Novogene currently consists of a comprehensive, and interdisciplinary team, the majority of which hold advanced degrees from top universities in China and abroad. The company has established high-flux, large-scale gene sequencing and high-performance computing platforms, which support effectively the demands of life science research and medical health for big data analysis and storage. Novogene has served over 7,300 global customers, covering 90 countries and regions across 6 continents. We have cooperated extensively with many academic institutions and completed several advanced-level, international genomics research projects. By 2023, Novogene has co-published and/or been acknowledged in more than 22,850 articles in Science Citation Index, with an accumulative impact factor of more than 148,250. Our partners are worldwide and include more than 4,200 scientfic research institutions and universities, more than 680 hospitals and over 2,400 pharmaceutical and agricultural enterprises. Currently, Novogene has obtained 356 software copyrights and 66 patents. As the leader in genome sequencing, Novogene’s business spans across scientific research for life science, medical research and technology services, storage-building sequencing platform services, gene sequencing, mass spectrometry and bio-information technology support for global research, scientific research institutions, hospitals, pharmaceutical R&D enterprises and agricultural enterprises.